Our goal is to develop transformative cell therapies for patients with a wide range of difficult to treat diseases.
Our founder and CEO, Dr. Armon Sharei, invented the Cell Squeeze® technology during his PhD in the laboratories of Dr. Klavs Jensen and Dr. Robert Langer at MIT. This innovation overcame major barriers to cell therapy development and implementation. SQZ Biotech was founded with the goal of creating a new generation of cell therapies – cell therapies that could enable transformative patient outcomes across disease areas while remaining safe and practical to administer.
Board of Directors
Amy Schulman | SQZ Biotech Chairwoman and Polaris Partner
Former Pfizer executive named one of Fortune’s 50 most powerful women in business in 2013.
Armon Sharei, PhD | SQZ Biotech® company founder and CEO
Inventor of the Cell Squeeze® technology. Selected as one of the 30 Under 30 in Healthcare by Forbes in 2015.
Paul Bolno, MD | President & CEO of Wave Life Sciences
Has a broad industry background in business development, investments, and commercial development.
Marc Elia | Founder of M28 Capital
Over 20 years of industry and finance experience in biotechnology.
Pushkal Garg, MD | CMO of Alnylam
Over 15 years of experience in clinical drug development. Deep experience in immunology with years in late-stage development at BMS.
Klavs Jensen, PhD | SQZ Biotech® company founder and Emeritus MIT Chemical Engineering Department Chair
Established leader in fabrication, testing, and integration of microsystems.
Eric Moessinger | Partner at NanoDimension
Involved in deal sourcing, due diligence and structuring focusing on NanoDimension’s life sciences investments.
Marc Schegerin, MD | CFO of Morphic Therapeutics
Established leader in biotech and corporate finance. Previously CFO of AqQUle through Merck acquisition and senior roles in healthcare investment banking.
Sapna Srivastava, PhD | Experienced CFO
Experienced board member and CFO, with roles in strategic planning, and in equity research across the industry. Experience includes leading Intellia as CFO through their IPO.
Scientific Advisory Board
Darrell Irvine, PhD | The Howard Hughes Medical Institute
In addition to positions at MIT, The Koch Institute, and The Ragon Institute, investigates immune engineering strategies for The Howard Hughes Medical Institute.
Tyler Jacks, PhD | The Koch Institute for Cancer Research and MIT
Director of The Koch Institute for Cancer Research and MIT professor breaking new ground in gene targeting strategies for cancer.
Robert Langer, ScD. | MIT Koch Institute
SQZ founder, MIT Koch Institute Professor, and most cited engineer in history renowned for his contributions to the fields of drug delivery and tissue engineering.
Mark Murcko, PhD | Relay Therapeutics
Founding CSO and BoD member of Dewpoint Therapeutics and former CTO and SAB Chair of Vertex. Over 25 years of leadership experience in the biomedical field. Key contributor to seven marketed drugs.
David Sachs, MD | Columbia and MGH
Thought leader in immune tolerance research, discovered MHC Class II antigens and initiated the first successful clinical trials of transplantation tolerance. Currently directs transplantation research at both Columbia and MGH.
Arlene Sharpe, MD, PhD. | Harvard and Brigham and Women’s Hospital
Co-developer of the anti-PD1 checkpoint blockade and co-director of The Evergrande Center for Immunologic Diseases at Harvard and Brigham and Women’s Hospital.
Mark Shlomchik, MD, PhD | University of Pittsburgh School of Medicine
Chair of the Department of Immunology at the University of Pittsburgh School of Medicine and leader in studies of B cell immune responses, B cell memory and systemic autoimmune diseases like SLE.
Ulrich von Andrian, MD, PhD | Harvard Medical School
Mallinckrodt Professor of Immunopathology at Harvard Medical School and leader in understanding the regulation and function of immune cells.
Kai Wucherpfennig, MD, PhD | Dana Farber
Chair of Cancer Immunology and Virology at Dana Farber. Established leader in the field with 35 years of experience; current research focus on T cell immunology and the role of T cells in cancer immunology.
Media (reporters & media outlets only)
For more information about the clinical trial, please visit ClinicalTrials.gov
200 Arsenal Yards Blvd, Suite 210
Watertown, MA 02472
Our headquarters are located at Arsenal Yards, an up-and-coming complex for life science companies, shopping, and entertainment. While Arsenal Yards is under construction, please use the following instructions to locate our office.
Please turn onto Arsenal Yards Boulevard, then into the parking garage above Chipotle, and park on the Visitor Level. From the parking garage, walk past Marshalls to the end of the shops and turn right after Shake Shack. Our entrance is on the end of the building.
Please proceed through the doors and take the stairs or elevator up to the lobby on the second floor. Please check-in using the iPad kiosk upon arrival.
These directions will change in the coming months as a new, closer parking garage opens. Please check back frequently for any updates! We appreciate your patience during this time.